300 Employee Construction Company
| Annualized Charges to the sponsor in excess of optimal pricing | $101,529 |
|---|---|
| Total valid prescriptions in the dataset (12 mos) | 11,164 |
| Prescriptions analyzed that showed variances from optimal pricing in this dataset | 6,707 |
| Percent of total prescriptions in this dataset that showed variances from optimal pricing | 60.1% |
| Average excess margin per prescription | $9.09/Rx |
| Annualized projected rebates returned to plan sponsor | $17,304 |
| Total Elimination of repackaging Annualized Savings | $11,744 |
| Annualized Savings from minimal formulary revision at 25% | $95,229 |
Gross Potential Annualized Savings
| ANNUALIZED SAVINGS | Conversion​ 25% | Conversion​ 50% | Conversion​ 100% |
|---|---|---|---|
| Removal of Drug Cost Markups: | $101,529 | $101,529 | $101,529 |
| Return of Rebates to Plan Sponsor: | $17,304 | $17,304 | $17,304 |
| Savings Potential with Formulary Conversion: | $95,229 | $171,026 | $322,619 |
| Elimination of Repackaging: | $11,744 | $11,744 | $11,744 |
| Return of Audit Recoveries | $5,872 | $5,872 | $5,872 |
| TOTAL ANNUALIZED SAVINGS | $231,678 | $304,475 | $459,068 |
